Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara
Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...
Auto-immune
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...
Jiangsu Hengrui’s Vunakizumab Receives NMPA Approval as First Homegrown Autoimmune IL-17A Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis
Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...
Bio-Thera Solutions Expands Reach with New Licensing Deal for Biosimilar BAT2306
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a new licensing agreement with Russian firm...
Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates
Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
Genor Biopharma Strikes Licensing Deal with TRC 2004 for Global Rights to GB261 Outside Greater China
China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity...
China’s NMPA Gives Tacit Nod to IASO Biotechnology’s IASO-782 for SLE Clinical Trials
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...
Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA
Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...
Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial
Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline...
Everest Medicines’ Velsipity Shows Positive Results in Largest Asian Phase III UC Trial
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced positive top-line...
Kymera Therapeutics’ Stock Soars on Sanofi’s Plans to Expand KT-474 Clinical Trials
Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that...
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...
Bio-Thera Solutions’ BAT1806 Biosimilar Receives European Commission Approval
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns
Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...